The HES1 Knockout A-549 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population for investigating HES1 function in lung adenocarcinoma. This product consists of a genetically diverse pool of cells with targeted disruption of the HES1 gene, achieved by Cas9-mediated editing and non-homologous end joining. The polyclonal format preserves heterogeneous editing outcomes, ensuring robust and reproducible results across experiments without clonal selection bias. The knockout is validated at the population level and is ready for use in functional assays.
The A-549 host cell line, established from a 58-year-old Caucasian male with lung adenocarcinoma, is an adherent epithelial model displaying type II alveolar characteristics. It serves as a standard for non-small cell lung cancer (NSCLC) studies, harboring wild-type TP53 and KRAS mutations and retaining the ability to undergo EMT and maintain CSC populations.
HES1 is a basic helix-loop-helix transcriptional repressor and primary effector of the Notch cascade. Notch receptor activation by ligands DLL4/JAG1 leads to NICD formation, which complexes with RBPJ and MAML1 to induce HES1 transcription. HES1 recruits corepressors TLE1?C3 and HDAC1/2 to silence targets including CDKN1B (p27) and CDKN1A (p21), fostering cell cycle progression and blocking differentiation. It also represses proneural factors ASCL1, NEUROG1, and ATOH1, and self-regulates via auto-repression. Modulatory inputs from TGF-beta, BMP, HIF1A, STAT3, NFKB1, and Wnt pathways further tune HES1 activity to govern cell fate decisions, stem cell maintenance, and proliferation.
In A-549 cells, HES1 sustains cancer stem cell traits and drives EMT, linking it to metastasis and therapeutic resistance. By repressing p27 and p21, HES1 promotes proliferation, and crosstalk with TGF-beta and JAK-STAT enhances invasiveness. Disrupting HES1 in this polyclonal knockout model uncouples these oncogenic networks, making it a valuable tool for dissecting Notch-dependent lung adenocarcinoma biology and for testing Notch inhibitor responses.
Applications include RT-qPCR and Western blotting for expression analysis, ChIP-qPCR for promoter occupancy, and reporter assays with HES1-responsive elements. Proliferation (BrdU/MTT), migration, and invasion assays are directly applicable, along with flow cytometry for stem cell markers CD133 and ALDH. The cells are also suited for high-throughput screening of Notch modulators. For more information, contact Ascent Research.
